News: Genmab A/S (GEN.CO)
Wed, Dec 4 2013
COPENHAGEN - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
COPENHAGEN, Dec 4 - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
COPENHAGEN, Nov 26 - Danish biotech company Genmab raised its full-year guidance after announcing it will receive an $8 million milestone payment from partner Janssen Biotech.
COPENHAGEN, Nov 26 - Danish biotech company Genmab A/S said on Tuesday: * Has reached the first milestone in its Daratumumab collaboration with Janssen Biotech * To receive $8 mln milestone payment from Janssen * Now sees 2013 revenue of 595-635 million Danish crowns from earlier 550-590 million crowns * Now sees 2013 operating result of continuing operations of between positive 35 million crowns and negative 30 million crowns, from earlier between negative 10 million crowns and
COPENHAGEN, Oct 23 - Danish biotech firm Genmab said on Wednesday:
COPENHAGEN - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab.
COPENHAGEN, Oct 10 - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab.
COPENHAGEN, Oct 4 - Danish biotech firm Genmab A/S and GlaxoSmithKline said on Friday: * Have applied to the Marketing Authorization to the European Medicines Agency (EMA) to broaden label for cancer drug Arzerra (ofatumumab) in combination with an alkylator-based therapy.
COPENHAGEN, Aug 14 - Higher royalty income helped Genmab more than halve its operating loss in the second quarter and the Danish biotech company said it expected a smaller full-year operating loss than it previously anticipated.
HELSINKI, July 4 - The following stocks may be affected by newspaper reports and other factors on Thursday:
- Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved
- Genmab Reaches Fourth Milestone in Lundbeck Collaboration
- Genmab Announces Expansion of DuoBody Platform Collaboration with Janssen Biotech, Inc.
- Genmab Reaches First Milestone in Daratumumab Collaboration With Janssen & Improves 2013 Financial Guidance
- Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2013
- Genmab to Present Product and Proprietary Technology data at American Society of Hematology Annual Meeting (ASH)
- Genmab Announces Financial Results for the First Nine Months of 2013
- Arzerra(r) Third Quarter 2013 Net Sales Figures
- GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra(r) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
- Genmab Announces Positive Top-Line Phase II Results of Ofatumumab in Multiple Sclerosis